The Portal venous Content of Microbial Molecules (PoCoMiMo) Study

The Portal venous Content of Microbial Molecules (PoCoMiMo) Study - PoCoMiMo-study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51237

Enrollment

Registered

2021-06-22

Start date

2021-08-19

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer pancreas cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult patients undergoing any of the following surgical interventions: • Partial hepatic resection for an underlying hepatic malignancy • Pancreaticoduodenectomy for a pancreatic malignancy • Living donor liver transplantation

Exclusion criteria

Exclusion criteria: Exclusion criteria are as follows: • Patients who are known to suffer from an active viral infection (e.g. hepatitis B or C) • Patients with severe portal hypertension • Patients who cannot provide informed consent due to cognitive impairment or language barrier

Design outcomes

Primary

Measure	Time frame
The primary study parameter is the intestinal uptake of microbiome-derived metabolites as defined by their enrichment between arterial (pre-intestinal) and post-intestinal (portal venous) blood samples.	—

Secondary

Measure	Time frame
Secondary outcomes are the association between intestinal uptake of metabolites with microbial features determined by metagenomic sequencing, and - in the subset of patients undergoing partial liver resection - the rate of hepatic clearance of microbial metabolites between pre-hepatic (portal venous) and post-hepatic (hepatic venous) blood samples in relation to hepatic gene expression of phase I and phase II biotransformation enzymes in a research liver biopsy.	—

Measure

Time frame

Secondary outcomes are the association between intestinal uptake of metabolites with microbial features determined by metagenomic sequencing, and - in the subset of patients undergoing partial liver resection - the rate of hepatic clearance of microbial metabolites between pre-hepatic (portal venous) and post-hepatic (hepatic venous) blood samples in relation to hepatic gene expression of phase I and phase II biotransformation enzymes in a research liver biopsy.

—

Countries

Netherlands

Outcome results